Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

Pavel Viktorovich Chernyshov; Lucia Tomas-Aragones; Torsten Zuberbier; Emek Kocatürk; Liana Manolache; Nives Pustisek; Åke Svensson; Servando E Marron; Francesca Sampogna; Anthony Bewley; Carmen Salavastru; Dimitra Koumaki; Matthias Augustin; Dennis Linder; Damiano Abeni; Sam S Salek; Jacek C Szepietowski; Gregor B Jemec

doi:10.1111/ijd.17366

Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

Pavel Viktorovich Chernyshov^*, Lucia Tomas-Aragones, Torsten Zuberbier, Emek Kocatürk, Liana Manolache, Nives Pustisek, Åke Svensson, Servando E Marron, Francesca Sampogna, Anthony Bewley, Carmen Salavastru, Dimitra Koumaki, Matthias Augustin, Dennis Linder, Damiano Abeni, Sam S Salek, Jacek C Szepietowski, Gregor B Jemec

^*Corresponding author af dette arbejde

Dermatologisk Afdeling

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient-Oriented Outcomes and Urticaria and Angioedema has examined the Health-Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.

Originalsprog	Engelsk
Sider (fra-til)	1657-1667
Antal sider	11
Tidsskrift	International Journal of Dermatology
Vol/bind	63
Udgave nummer	12
Tidlig onlinedato	4 jul. 2024
DOI	https://doi.org/10.1111/ijd.17366
Status	Udgivet - dec. 2024

Adgang til dokumentet

10.1111/ijd.17366

Citationsformater

Chernyshov, P. V., Tomas-Aragones, L., Zuberbier, T., Kocatürk, E., Manolache, L., Pustisek, N., Svensson, Å., Marron, S. E., Sampogna, F., Bewley, A., Salavastru, C., Koumaki, D., Augustin, M., Linder, D., Abeni, D., Salek, S. S., Szepietowski, J. C., & Jemec, G. B. (2024). Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement. International Journal of Dermatology, 63(12), 1657-1667. https://doi.org/10.1111/ijd.17366

@article{a5781c20905a4f8fa06036001991e3a0,

title = "Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement",

abstract = "In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient-Oriented Outcomes and Urticaria and Angioedema has examined the Health-Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.",

keywords = "Europe, Humans, Minimal Clinically Important Difference, Quality of Life, Severity of Illness Index, Surveys and Questionnaires/statistics \& numerical data, Treatment Outcome, Urticaria/drug therapy",

author = "Chernyshov, \{Pavel Viktorovich\} and Lucia Tomas-Aragones and Torsten Zuberbier and Emek Kocat{\"u}rk and Liana Manolache and Nives Pustisek and {\AA}ke Svensson and Marron, \{Servando E\} and Francesca Sampogna and Anthony Bewley and Carmen Salavastru and Dimitra Koumaki and Matthias Augustin and Dennis Linder and Damiano Abeni and Salek, \{Sam S\} and Szepietowski, \{Jacek C\} and Jemec, \{Gregor B\}",

note = "{\textcopyright} 2024 the International Society of Dermatology.",

year = "2024",

month = dec,

doi = "10.1111/ijd.17366",

language = "English",

volume = "63",

pages = "1657--1667",

journal = "International Journal of Dermatology",

issn = "0011-9059",

publisher = "John Wiley \& Sons Inc.",

number = "12",

}

Chernyshov, PV, Tomas-Aragones, L, Zuberbier, T, Kocatürk, E, Manolache, L, Pustisek, N, Svensson, Å, Marron, SE, Sampogna, F, Bewley, A, Salavastru, C, Koumaki, D, Augustin, M, Linder, D, Abeni, D, Salek, SS, Szepietowski, JC & Jemec, GB 2024, 'Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement', International Journal of Dermatology, bind 63, nr. 12, s. 1657-1667. https://doi.org/10.1111/ijd.17366

TY - JOUR

T1 - Quality of life measurement in assessing treatment effectiveness in urticaria

T2 - European experts position statement

AU - Chernyshov, Pavel Viktorovich

AU - Tomas-Aragones, Lucia

AU - Zuberbier, Torsten

AU - Kocatürk, Emek

AU - Manolache, Liana

AU - Pustisek, Nives

AU - Svensson, Åke

AU - Marron, Servando E

AU - Sampogna, Francesca

AU - Bewley, Anthony

AU - Salavastru, Carmen

AU - Koumaki, Dimitra

AU - Augustin, Matthias

AU - Linder, Dennis

AU - Abeni, Damiano

AU - Salek, Sam S

AU - Szepietowski, Jacek C

AU - Jemec, Gregor B

PY - 2024/12

Y1 - 2024/12

N2 - In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient-Oriented Outcomes and Urticaria and Angioedema has examined the Health-Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.

AB - In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient-Oriented Outcomes and Urticaria and Angioedema has examined the Health-Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.

KW - Europe

KW - Humans

KW - Minimal Clinically Important Difference

KW - Quality of Life

KW - Severity of Illness Index

KW - Surveys and Questionnaires/statistics & numerical data

KW - Treatment Outcome

KW - Urticaria/drug therapy

U2 - 10.1111/ijd.17366

DO - 10.1111/ijd.17366

M3 - Review

C2 - 38965063

SN - 0011-9059

VL - 63

SP - 1657

EP - 1667

JO - International Journal of Dermatology

JF - International Journal of Dermatology

IS - 12

ER -

Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater